Development of an antigen detection assay for early point-of-care diagnosis of Zaire ebolavirus

被引:7
|
作者
DeMers, Haley L. [1 ]
He, Shihua [2 ]
Pandit, Sujata G. [1 ]
Hannah, Emily E. [1 ]
Zhang, Zirui [2 ,3 ]
Yan, Feihu [3 ]
Green, Heather R. [1 ]
Reyes, Denise F. [1 ]
Hau, Derrick [1 ]
McLarty, Megan E. [1 ]
Altamura, Louis [4 ,5 ]
Taylor-Howell, Cheryl [4 ]
Gates-Hollingsworth, Marcellene A. [1 ]
Qiu, Xiangguo [2 ]
AuCoin, David P. [1 ]
机构
[1] Univ Nevada, Dept Microbiol & Immunol, Reno Sch Med, Reno, NV 89557 USA
[2] Publ Hlth Agcy Canada, Special Pathogens Program, Natl Microbiol Lab, Winnipeg, MB, Canada
[3] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada
[4] US Army, Med Res Inst Infect Dis, Diagnost Syst Div, Ft Detrick, MD 21702 USA
[5] US Dept Homeland Secur, Natl Biodefense Anal & Countermeasures Ctr, Natl Biodef Inst, Frederick, MD USA
来源
PLOS NEGLECTED TROPICAL DISEASES | 2020年 / 14卷 / 11期
关键词
VIRUS-LIKE PARTICLES; MATRIX PROTEIN; VIRION GLYCOPROTEINS; HEMORRHAGIC-FEVER; WEST-AFRICA; DISEASE; VP40; TRANSCRIPTION; MECHANISM;
D O I
10.1371/journal.pntd.0008817
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The 2013-2016 Ebola virus (EBOV) outbreak in West Africa and the ongoing cases in the Democratic Republic of the Congo have spurred development of a number of medical countermeasures, including rapid Ebola diagnostic tests. The likelihood of transmission increases as the disease progresses due to increasing viral load and potential for contact with others. Early diagnosis of EBOV is essential for halting spread of the disease. Polymerase chain reaction assays are the gold standard for diagnosing Ebola virus disease (EVD), however, they rely on infrastructure and trained personnel that are not available in most resource-limited settings. Rapid diagnostic tests that are capable of detecting virus with reliable sensitivity need to be made available for use in austere environments where laboratory testing is not feasible. The goal of this study was to produce candidate lateral flow immunoassay (LFI) prototypes specific to the EBOV glycoprotein and viral matrix protein, both targets known to be present during EVD. The LFI platform utilizes antibody-based technology to capture and detect targets and is well suited to the needs of EVD diagnosis as it can be performed at the point-of-care, requires no cold chain, provides results in less than twenty minutes and is low cost. Monoclonal antibodies were isolated, characterized and evaluated in the LFI platform. Top performing LFI prototypes were selected, further optimized and confirmed for sensitivity with cultured live EBOV and clinical samples from infected non-human primates. Comparison with a commercially available EBOV rapid diagnostic test that received emergency use approval demonstrates that the glycoprotein-specific LFI developed as a part of this study has improved sensitivity. The outcome of this work presents a diagnostic prototype with the potential to enable earlier diagnosis of EVD in clinical settings and provide healthcare workers with a vital tool for reducing the spread of disease during an outbreak.
引用
收藏
页数:19
相关论文
共 50 条
  • [41] Accuracy of Point-of-Care Rapid Antigen Tests for Diagnosis of COVID-19
    Clebak, Karl T.
    Snyder, Jessica
    Felix, Todd M.
    AMERICAN FAMILY PHYSICIAN, 2023, 107 (04) : 354 - 355
  • [42] Point-of-care diagnosis of COVID-19 disease based on antigen tests
    Pohanka, M.
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2021, 122 (11): : 763 - 770
  • [43] Biomarker Detection in Early Diagnosis of Cancer: Recent Achievements in Point-of-Care Devices Based on Paper Microfluidics
    Erkocyigit, Bilge Asci
    Ozufuklar, Ozge
    Yardim, Aysenur
    Celik, Emine Guler
    Timur, Suna
    BIOSENSORS-BASEL, 2023, 13 (03):
  • [44] Point-of-care HIV early infant diagnosis: is test sensitivity everything?
    Dunning, Lorna
    Hsiao, Nei-yuan
    Myer, Landon
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2015, 18
  • [45] Early diagnosis of lower respiratory tract infections (point-of-care tests)
    Charles, Patrick G. P.
    CURRENT OPINION IN PULMONARY MEDICINE, 2008, 14 (03) : 176 - 182
  • [46] Development and validation of a point-of-care breath test for octane detection
    Hagens, Laura A.
    Verschueren, Alwin R. M.
    Lammers, Ariana
    Heijnen, Nanon F. L.
    Smit, Marry R.
    Nijsen, Tamara M. E.
    Geven, Inge
    Schultz, Marcus J.
    Bergmans, Dennis C. J. J.
    Schnabel, Ronny M.
    Bos, Lieuwe D. J.
    ANALYST, 2021, 146 (14) : 4605 - 4614
  • [47] Detection of skin allergy biomarkers for point-of-care diagnosis of contact dermatitis
    Lefevre, M-A
    Nosbaum, A.
    Mosnier, A.
    Lenief, V.
    Salque, S.
    Pichot, M.
    Maheux, L.
    Bertolotti, L.
    Hacard, F.
    Graveriau, C.
    Zukervar, P.
    Guitarian, A-L Breton
    Boisleve, F.
    Elbaz, M.
    Nicolas, J-F
    Vocanson, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S369 - S369
  • [48] Nanoparticle Detection of Urinary Markers for Point-of-Care Diagnosis of Kidney Injury
    Chung, Hyun Jung
    Pellegrini, Kathryn L.
    Chung, Jaehoon
    Wanigasuriya, Kamani
    Jayawardene, Innocent
    Lee, Kyungheon
    Lee, Hakho
    Vaidya, Vishal S.
    Weissleder, Ralph
    PLOS ONE, 2015, 10 (07):
  • [49] Evaluation of a point-of-care assay for detection of bladder cancer in women at risk.
    Katz, G
    Ross, MG
    JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION, 2006, 13 (02) : 172A - 172A
  • [50] An integrated microfluidic electrochemical assay for cervical cancer detection at point-of-care testing
    Keyvani, Fatemeh
    Debnath, Nandini
    Saleh, Mahmoud Ayman
    Poudineh, Mahla
    NANOSCALE, 2022, 14 (18) : 6761 - 6770